MedTrace Logo

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-02-24

No results posted yet for this study

Summary

This is a phase 2, randomized, open-label, single-center study that will assess the efficacy of TriCalm Hydrogel®, a topical gel containing strontium, for treating pruritus related to immune checkpoint inhibitors (ICIs).

Conditions

  • Immunotherapy-related Pruritus

Interventions

DRUG

Tricalm Hydrogel

TriCalm Hydrogel® is a topical gel that allows rapid administration to areas of the skin. TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.

DRUG

Triamcinolone acetonide 0.1% cream

Triamcinolone acetonide 0.1% cream is a topical steroid cream that will be applied directly to the skin.

Sponsors & Collaborators

Principal Investigators

  • Karen M Yun, MD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06748404 on ClinicalTrials.gov